Uncertainty in Market Evaluation in Product Development
First written in FY2016. 10 of 14 entries say "Restated". Latest entry: FY2023.
The whole theme swung hardest in 2024: 3 of 11 companies on the "Worse" side.
19 other companies' latest entry also says "Restated".
- FY2023RestatedAnnual report
「We recognize product development as an important challenge in securing stable earnings. However, product development may fail to progress due to personnel, funding and other factors. Even if we succeed in developing the targeted product, it will still be subject to market evaluation. If we are unable to adequately anticipate changes in the market and our competitiveness relative to other companies declines, this may affect our business performance.」
The risks of stalled product development, market evaluation and declining competitiveness due to market changes continue to be disclosed. - FY2021RestatedAnnual report
「We recognize product development as an important challenge in securing stable earnings. However, product development may fail to progress due to personnel, funding and other factors. Even if we succeed in developing the targeted product, it will still be subject to market evaluation. If we are unable to adequately anticipate changes in the market and our competitiveness relative to other companies declines, this may affect our business performance.」
The explanation of risks continues to include stalled product development, market evaluation and declining competitiveness due to market changes. - FY2020ReframedAnnual report
「We recognize product development as an important challenge in securing stable earnings. However, product development may fail to progress due to personnel, funding and other factors. Even if we succeed in developing the targeted product, it will still be subject to market evaluation. If we are unable to adequately anticipate changes in the market and our competitiveness relative to other companies declines, this may affect our business performance.」
In addition to the existing uncertainty regarding market evaluation, the scope of the risk explanation has been expanded to include stalled development due to personnel and funding factors, as well as declining competitiveness due to market changes. - FY2020-Q2RestatedAnnual report
「During the cumulative second-quarter period, no new business or other risks arose. In addition, there were no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
It is stated that there have been no new developments or material changes regarding uncertainty in market evaluation in product development. - FY2020-Q1RestatedAnnual report
「During the cumulative first quarter of the current fiscal year, there were no occurrences of matters concerning the business situation, accounting situation or other matters described in the quarterly report that could have a material impact on investors’ decisions, and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
It is stated that there have been no material developments or changes regarding uncertainty in market evaluation in product development. - FY2019RestatedAnnual report
「The Company develops products independently based on market research, but because they are subject to market evaluation, it cannot make timely and accurate decisions.」
The risk that market evaluation cannot be accurately assessed in advance in connection with internally developed products continues to be identified. - FY2019-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
It has been explained that there have been no new developments or material changes regarding uncertainty in market evaluation in product development. - FY2019-Q2RestatedAnnual report
「During the cumulative second-quarter period, no new business or other risks arose. In addition, there were no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
It has been explained that there have been no new developments or material changes regarding uncertainty in market evaluation in product development. - FY2018RestatedAnnual report
「The Company develops products independently based on market research, but because they are subject to market evaluation, it cannot make timely and accurate decisions.」
The risk that market evaluation of internally developed products cannot be assessed accurately and in a timely manner in advance continues to be identified. - FY2018-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
It has been explained that there have been no new developments or material changes regarding uncertainty in market evaluation in product development. - FY2018-Q2RestatedAnnual report
「During the cumulative second-quarter period, no new business or other risks arose. In addition, there were no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
It has been explained that there have been no material changes in the risks related to product development and market evaluation. - FY2017MaterialisedAnnual report
「However, the main factors behind the sluggish growth in sales were that we had to proceed with sales activities while verifying the effects of the initial installations and had to devote time to informing customers about the product’s functions and efficacy.」
It has been explained that verifying the effectiveness of the initial implementation and informing the market about the product's functions and benefits took time, and that the impact of uncertainty actually emerged as sluggish revenue growth. - FY2017-Q3MitigatedAnnual report
「However, as this is an initial implementation, we are proceeding while verifying its effectiveness. The results are favorable at this stage, and we expect to recognize revenue in the fourth quarter.」
Verification of the effectiveness of the initial implementation is ongoing, but the results at this stage have been described as favorable, indicating that measures to address uncertainty regarding product effectiveness are progressing. - FY2016First statedAnnual report
「The Company develops products independently based on market research, but because they are subject to market evaluation, it cannot make timely and accurate decisions.」
This indicates the risk that market acceptance of internally developed products cannot be accurately assessed in advance.